Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.42 USD | -0.74% | +1.47% | +1.65% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Financials (USD)
Sales 2024 * | 663M | Sales 2025 * | 166M | Capitalization | 9.2B |
---|---|---|---|---|---|
Net income 2024 * | 4.25B | Net income 2025 * | -1.01B | EV / Sales 2024 * | 5.35 x |
Net cash position 2024 * | 5.65B | Net cash position 2025 * | 4.39B | EV / Sales 2025 * | 29 x |
P/E ratio 2024 * |
2.21
x | P/E ratio 2025 * |
-8.69
x | Employees | 904 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.81% |
Latest transcript on Roivant Sciences Ltd.
1 day | -0.74% | ||
1 week | +1.83% | ||
Current month | +4.72% | ||
1 month | +5.30% | ||
3 months | -0.31% | ||
6 months | +25.85% | ||
Current year | +1.65% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 16-02-29 |
Richard Pulik
DFI | Director of Finance/CFO | - | 21-09-27 |
Eric Venker
PSD | President | 37 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 23-03-12 | |
Keith Manchester
BRD | Director/Board Member | 55 | 13-12-31 |
Dan Gold
BRD | Director/Board Member | 56 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 11.41 | -0.78% | 3,057,456 |
24-05-15 | 11.5 | +1.50% | 2,900,374 |
24-05-14 | 11.33 | +1.34% | 2,638,766 |
24-05-13 | 11.18 | +0.45% | 2,272,515 |
24-05-10 | 11.13 | -1.07% | 2,569,934 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.65% | 9.27B | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- ROIV Stock